According to DelveInsight’s analysis, the global Non-Cystic Fibrosis Bronchiectasis pipeline features over 16 leading companies actively advancing more than 17 therapeutic candidates, with ongoing evaluations of their clinical trials, mechanisms of action, routes of administration, and developmental progress.
DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2025” report delivers a thorough overview of the current clinical landscape and future opportunities within the Non-Cystic Fibrosis Bronchiectasis market. The report offers an extensive commercial and clinical evaluation of pipeline therapies, spanning from preclinical stages to approved products. It includes detailed profiles of each drug candidate, covering their mechanisms of action, clinical trial progress, regulatory milestones, and product development updates such as technological advancements, partnerships, mergers and acquisitions, funding activities, designations, and other relevant attributes.
Request for Sample Report @ Non-Cystic Fibrosis Bronchiectasis Pipeline Outlook
Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report:
Non-Cystic Fibrosis Bronchiectasis Overview
Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic, progressive respiratory condition characterized by permanent dilation of the airways, leading to persistent cough, excessive mucus production, and recurrent lung infections. Unlike cystic fibrosis-related bronchiectasis, NCFB arises from various underlying causes such as severe respiratory infections, immune deficiencies, allergic reactions, and genetic disorders. The disease is driven by an ongoing cycle of inflammation and infection, which gradually worsens lung function and quality of life. Diagnosis typically involves CT imaging, sputum analysis, and lung function tests, while treatment focuses on airway clearance therapies, antibiotics, bronchodilators, and emerging targeted approaches to control inflammation and prevent exacerbations.
Get a Free Sample PDF Report to know more about the phases of drugs in development, ROA and MOA , click here @ Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment
Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include:
Non-Cystic Fibrosis Bronchiectasis Route of Administration
Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Non-Cystic Fibrosis Bronchiectasis Molecule Type
Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as
Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment
DelveInsight’s Non-Cystic Fibrosis Bronchiectasis Report covers around 17+ products under different phases of clinical development like
Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies @ Non-Cystic Fibrosis Bronchiectasis Treatment Market
Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include:
Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are – Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others.
Emerging Therapies for Non-Cystic Fibrosis Bronchiectasis
Brensocatib (INS1007/AZD7986) is an oral, reversible small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1). DPP1 activates neutrophil serine proteases (NSPs), including neutrophil elastase, during neutrophil development in the bone marrow. By blocking DPP1, Brensocatib aims to reduce neutrophil-driven inflammation that contributes to bronchiectasis. Insmed licensed the therapy from AstraZeneca in 2016, and it is currently under evaluation in Phase III clinical trials for Non-Cystic Fibrosis Bronchiectasis.
HSK31858 is a highly selective, potent, orally administered DPP1 inhibitor developed by Haisco Pharmaceutical. By preventing DPP1-mediated activation of neutrophils and related NSP enzymes, the therapy seeks to limit excessive inflammatory responses in the lower respiratory tract. It is being investigated for conditions such as bronchiectasis and acute lung injury/ARDS. Phase I studies in Australia and China have been completed, and Phase II trials are now underway with positive progress.
CSL787 is a nebulized human plasma-derived immunoglobulin designed to help prevent recurring respiratory infections and slow the progression of chronic lung diseases, including Non-Cystic Fibrosis Bronchiectasis. The therapy is currently in Phase I clinical development.
Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies – Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Advancements
Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers
Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market.
Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers
However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth.
Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight
Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials – Non-Cystic Fibrosis Bronchiectasis Companies and Drugs
Table of Contents
1. Non-Cystic Fibrosis Bronchiectasis Report Introduction
2. Non-Cystic Fibrosis Bronchiectasis Executive Summary
3. Non-Cystic Fibrosis Bronchiectasis Overview
4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment
5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics
6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III)
7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II)
8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I)
9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products
10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment
11. Non-Cystic Fibrosis Bronchiectasis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Cystic Fibrosis Bronchiectasis Key Companies
14. Non-Cystic Fibrosis Bronchiectasis Key Products
15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers
17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion
18. Non-Cystic Fibrosis Bronchiectasis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting/primary-research-services
